Journal
CANCER RESEARCH AND TREATMENT
Volume 49, Issue 4, Pages 898-905Publisher
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2016.312
Keywords
Adjuvant chemotherapy; Stage IB; Adenocarcinoma; High risk
Categories
Funding
- R&D program of the Korean Ministry of Knowledge and Economy/Korea Evaluation Institute of Industrial Technology (MKE/KEIT) [10040393]
- Korean Foundation for Cancer Research [CB-2011-02-01]
- Korea Evaluation Institute of Industrial Technology (KEIT) [10040393] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Purpose We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with pathologic stage IB lung adenocarcinoma who had undergone complete resection and were defined as high-risk by a newly developed recurrence risk scoring model. Materials and Methods Patients who underwent curative resection for stage IB lung adenocarcinoma were analyzed with a newly developed recurrence risk scoring model and divided into a low-risk group and a high-risk group. The patients in the high-risk group were retrospectively divided into two groups based on whether they underwent adjuvant chemotherapy or observation. Recurrence- free survival and overall survival were compared between these two groups. Results A total of 328 patients who underwent curative resection between 2000 and 2009 were included in this study, of whom 110 (34%) received adjuvant chemotherapy and 218 (67%) underwent observation without additional treatment. According to our risk model, 167 patients (51%) were high-risk and 161 (49%) were low-risk. The 5-year recurrence-free survival rates and overall survival were 84.4% and 91.5% in low-risk patients and 53.9% and 74.7% in high-risk patients (p < 0.001). In high-risk patients, the 5-year overall survival rates were 77% among patients who underwent observation and 87% among those who underwent adjuvant chemotherapy (p=0.019). Conclusion Adjuvant chemotherapy prolonged overall survival among high-risk patients who had undergone complete resection for stage IB lung adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available